An analysis of stem cell training programs for physicians in the US-A mirage of credibility
Ellythy L., Addani M., Master Z.
Laboratory Study, published in Stem Cell Reports (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Stem Cell Reports (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40446797
- PMCID
- PMC12181954
- DOI
- 10.1016/j.stemcr.2025.102510
- Citations
- 1
Abstract (original English)
Analyzing stem cell training businesses for United States (US) physicians shows the use of sensationalized marketing language emphasizing profits and growth with many of the instructors affiliated with clinics providing unproven therapies. We argue that many current pedagogical offerings for physicians interested in stem cell interventions are likely to offer questionable training and outline red flags for physicians interested in stem cell therapies.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.